Vitality Biopharma Inc (OTCMKTS:VBIO) Participates In International Research Symposium

Vitality Biopharma Inc (OTCMKTS:VBIO) a firm looking into the innovation of CBDs prodrug pharmaceuticals, and unveiling the usefulness of CBDs for the inflammatory and neurological problems, reported that firm consultant Dr. Natasha Ryz represented the firm at a global research symposium that was scheduled in Montreal.

The buzz

Dr. Ryz offered a poster presentation on the report related to CBD treatment prompts remission in medicine-resistant Pediatric IBD. This report provided clinical data demonstrating a 13-year old child suffering with drug-resistant grave Crohn’s disease that saw disease remission following CBD treatment. Dr. Ryz has earned a Ph.D. in Experimental Medicine from a reputed university.

The scientific meeting marked the 27th ICRS Annual Symposium. It was scheduled from June 23 to June 26, 2017 in Montréal. The ICRS is a worldwide association of known researchers that assess CBDs, and the research plan at conference comprises different presentations linked to inflammatory bowel disease as well as gastroenterology.

ICRS Symposium comprised demonstrations by independent investigators that determined basic research on the active factor of the endocannabinoid mechanism in colitis. It also covered clinical research related to cannabis usefulness on drug-resilient ulcerative colitis.

In unrelated PR, Vitality Biopharma updated that it has acquired encouraging data demonstrating antimicrobial activity of CBDs and progressed with patent protection on CBD compounds targeting microbes, such as superbug pathogen and Clostridium difficile.

Using a list of the prime drug-resistant pathogens from the CDC, firm researchers looked for antimicrobial activity in compounds portfolio. Vitality noted fresh antimicrobial happenings related to CBDs, and as a result has progressed patent protection related to CBDs and CBDs prodrugs use for the cure of different pathogenic bacterial infections.

The firm successfully demonstrated antimicrobial reactivity of CBD on C. diff, and is presently working on follow-on studies intended to permit pharmaceutical application of advanced CBD prodrugs for the mentioned uses.